RT Journal Article
T1 MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.
A1 Belvís, Robert
A1 Irimia, Pablo
A1 Pozo-Rosich, Patricia
A1 González-Oria, Carmen
A1 Cano, Antonio
A1 Viguera, Javier
A1 Sánchez, Belén
A1 Molina, Francisco
A1 Beltrán, Isabel
A1 Oterino, Agustín
A1 Cuadrado, Elisa
A1 Gómez-Camello, Angel
A1 Alberte-Woodward, Miguel
A1 Jurado, Carmen
A1 Oms, Teresa
A1 Ezpeleta, David
A1 de Terán, Javier Díaz
A1 Morollón, Noemí
A1 Latorre, Germán
A1 Torres-Ferrús, Marta
A1 Alpuente, Alicia
A1 Lamas, Raquel
A1 Toledano, Carlos
A1 Leira, Rogelio
A1 Santos, Sonia
A1 Del Río, Margarita Sánchez
K1 Erenumab
K1 Migraine
K1 Monoclonal antibody
K1 Preventive treatment
K1 Registry
AB Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results. Patients fulfilled the ICHD-3 criteria for migraine and had ≥ 4 MMDs. Sociodemographic and clinical data were registered as well as MMDs, monthly headache days, MHDs, prior and concomitant preventive treatment, medication overuse headache (MOH), migraine evolution, adverse events, and patient-reported outcomes (PROs): headache impact test (HIT-6), migraine disability assessment questionnaire (MIDAS), and patient global improvement change (PGIC). A > 50% reduction of MMDs after 12 weeks was considered as a response. We included 210 patients (female 86.7%, mean age 46.4 years old) from 22 Spanish hospitals from February 2019 to June 2020. Most patients (89.5%) suffered from chronic migraine with a mean evolution of 8.6 years. MOH was present in 70% of patients, and 17.1% had migraine with aura. Patients had failed a mean of 7.8 preventive treatments at baseline (botulinum toxin type A-BoNT/A-had been used by 95.2% of patients). Most patients (67.6%) started with erenumab 70 mg. Sixty-one percent of patients were also simultaneously taking oral preventive drugs and 27.6% were getting simultaneous BoNT/A. Responder rate was 37.1% and the mean reduction of MMDs and MHDs was -6.28 and -8.6, respectively. Changes in PROs were: MIDAS: -35 points, HIT-6: -11.6 points, PIGC: 4.7 points. Predictors of good response were prior HIT-6 score  In real-life, in a personalized managed access program, erenumab shows a good effectiveness profile and an excellent tolerability in migraine prevention in our cohort of refractory patients.
YR 2021
FD 2021-07-17
LK http://hdl.handle.net/10668/18210
UL http://hdl.handle.net/10668/18210
LA en
DS RISalud
RD Apr 10, 2025